Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- JANSSEN PHARMA NV
- Publication Date
- 2020-11-27
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] Cross References to Related Applications
[0002] This application claims priority to PCT Application PCT / US2018 / 029284, filed April 25, 2018, and US Provisional Application 62 / 662,313, filed April 25, 2018. The entirety of each publication is incorporated herein by reference. technical field
[0003] The present invention generally relates to novel glucagon-like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine-tyrosine (PYY) conjugates, which are neuropeptide Y2 receptors and GLP-1 Modulators of receptors. The invention also relates to pharmaceutical compositions and methods of their use. The novel GLP-1 fusion peptide-coupled cyclic PYY conjugate can be used to prevent, treat or improve diseases and disorders such as obesity, type 2 diabetes, metabolic syndrome, insulin resistance and dyslipidemia.
[0004] Reference Sequence Listing Submitted Electronically
[0005] This application contains a Sequence Listing submitted electronically via EFS-W...